Translation, cultural adaptation and validation of the English “Short form SF 12v2” into Bengali in rheumatoid arthritis patients

Background: To develop a culturally adapted and validated Bengali Short Form SF 12v2 among Rheumatoid arthritis (RA) patients. Methods: The English SF 12v2 was translated, adapted and back translated into and from Bengali, pre-tested by 60 patients. The Bengali SF 12v2 was administered twice with 14 days interval to 130 Bangladeshi RA patients. The psychometric properties of the Bengali SF 12v2 were assessed. Test-retest reliability was assessed by intra-class correlation coefficient (ICC) and Spearman's rank correlation coefficient and internal consistency by Cronbach's alpha. Content validity was assessed by index for content validity (ICV) and floor and ceiling effects. To determine convergent and discriminant validity a Bengali Health Assessment Questionnaire (B-HAQ) was used. Factor analysis was done. Results: The Bengali SF 12v2 was well accepted by the patients in the pre-test and showed good reliability. Internal consistency for both physical and mental component was satisfactory; Cronbach's alpha was 0.9. ICC exceeded 0.9 in all domains. Spearman's rho for all domains exceeded 0.8. The physical health component of Bengali SF 12v2 had convergent validity to the B-HAQ. Its mental health component had discriminant validity to the B-HAQ. The ICV of content validity was 1 for all items. Factor analysis revealed two factors a physical and a mental component. Conclusions: The interviewer-administered Bengali SF 12v2 appears to be an acceptable, reliable, and valid instrument for measuring health-related quality of life in Bengali speaking RA patients. Further evaluation in the general population and in different medical conditions should be done

Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology

Supported by the Office of International Affairs, National Cancer Institute (NCI), the "US-Japan Workshop on Immunological Biomarkers in Oncology" was held in March 2009. The workshop was related to a task force launched by the International Society for the Biological Therapy of Cancer (iSBTc) and the United States Food and Drug Administration (FDA) to identify strategies for biomarker discovery and validation in the field of biotherapy. The effort will culminate on October 28th 2009 in the "iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", which will be held in Washington DC in association with the Annual Meeting. The purposes of the US-Japan workshop were a) to discuss novel approaches to enhance the discovery of predictive and/or prognostic markers in cancer immunotherapy; b) to define the state of the science in biomarker discovery and validation. The participation of Japanese and US scientists provided the opportunity to identify shared or discordant themes across the distinct immune genetic background and the diverse prevalence of disease between the two Nations

“European Commission Initiative on Breast Cancer”: Recomendaciones seleccionadas de cribado de cáncer de mama de las guías europeas

Background: The European Commission Initiative on Breast Cancer (ECIBC) has developed new recommendations on breast cancer screening and diagnosis. The objective of this work was to adapt these recommendations to Spanish in order to implement and guarantee the quality and success of breast cancer screening programmes (PCCM) throughout the Spanish territory. Methods: The new European Guidelines on Screening and Diagnosis of Breast Cancer have been prepared by a multidisciplinary panel of experts and patients (Guidelines Development Group, GDG). The recommendations included are supported by systematic reviews of the evidence conducted by a team of researchers from the Ibero-American Cochrane Center. For its preparation, the European Commission’s conflict of interest management rules were applied and the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology was used. The GRADE evidence-to-decision (EtD) frameworks were used to minimize potential influence of interests on the recommendations. Results: As a result of the systematic reviews carried out, the GDG published on the ECIBC website a list of recommendations as part of the guidelines for the screening and diagnosis of breast cancer, which were translated into Spanish in this work. Conclusions: The adaptation to Spanish of the new recommendations helps their implementation and the creation of a uniform PCCM throughout the Spanish territory. All of this improves informed decision making and the success of PCCM.Fundamentos: La European Commission Initiative on Breast Cancer (ECIBC) ha desarrollado nuevas recomendaciones sobre cribado y diagnóstico de cáncer de mama. El objetivo de este trabajo fue adaptar dichas recomendaciones al castellano con el fin de implementar y garantizar la calidad y el éxito de los programas de cribado de cáncer de mama (PCCM) en todo el territorio español. Métodos: Las nuevas Guías Europeas sobre Cribado y Diagnóstico de Cáncer de Mama han sido elaboradas por un panel multidisciplinar de expertos y pacientes (Guidelines Development Group, GDG). Las recomendaciones que se incluyen se apoyan en revisiones sistemáticas de la evidencia realizadas por un equipo de investigadores del Centro Cochrane Iberoamericano. Para su elaboración se aplicaron las reglas de manejo de conflicto de intereses de la Comisión Europea y se utilizó la metodología GRADE (Grading of Recommendations Assessment, Development and Evaluation). Se utilizaron los marcos de la evidencia a la decisión (EtD) de GRADE para minimizar posibles influencias de intereses en las recomendaciones. Resultados: Como resultado de las revisiones sistemáticas realizadas, el GDG publicó en la web de la ECIBC una lista de recomendaciones como parte de las guías para el cribado y diagnóstico del cáncer de mama, que fueron traducidas al castellano en este trabajo. Conclusiones: La adaptación al castellano de las nuevas recomendaciones ayuda a su implementación y a crear un PCCM uniforme en todo el territorio español. Todo ello mejora la toma de decisiones informadas y el éxito de los PCCM

Evaluación de un programa de salud pública sobre diagnostico precoz de VIH con prueba rápida

Background: The use of HIV planned and structured, community-based rapid tests is one of the main strategies for the early detection of HIV infection. The objective of the study was to assess the HIV early diagnosis programme with rapid test in the Region of Murcia. Methods: Descriptive analysis of the programme users’ epidemiological data during the years 2016 to 2018. Variables related to sociodemographic characteristics, risk exposure, history of HIV test performance and its result were analyzed. All analyzes were performed with statistical software IBM SPSS25 and Microsoft Excel version 2013. Frequencies were calculated in absolute values and the variables of interest were crosshead. Results: There were 1,023 people tested, of which 74% performed risky sexual practices in the last 12 months, both homosexual (50%) and heterosexual (45%), with an age between 18 and 40 years. 18.2% of the users were foreigners and 61.9% had been previously tested. Among the participants in the programme the percentage of reactive tests was 2.1% and the contribution to the diagnosis of new HIV cases in the Region was 4.3%. Conclusions: The results of the study show that the community-based programme is an effective tool for the diagnosis of HIV infection in vulnerable groups. In addition, several opportunities for improvement were identified in the process assessment, such as accessibility to the program and the collection of information.Fundamentos: Entre las principales estrategias para la detección precoz de la infección por VIH se encuentra la utilización planificada y estructurada de pruebas rápidas en entornos comunitarios especialmente vulnerables. El objetivo del presente estudio fue evaluar el programa de diagnóstico precoz de VIH con prueba rápida de la Región de Murcia. Métodos: Se realizó un análisis descriptivo de los datos epidemiológicos de la población participante en el programa durante los años 2016 a 2018. Se analizaron variables relacionadas con características sociodemográficas, exposición de riesgo, antecedentes de realización de la determinación de VIH y resultado de la prueba. Todos los análisis se realizaron con el software estadístico IBM SPSS25 y Microsoft Excel versión 2013. Se calcularon frecuencias en valores absolutos y los porcentajes correspondientes, y se cruzaron las variables de interés. Resultados: Se caracterizaron 1.023 personas participantes, de las que el 74% realizaron prácticas sexuales de riesgo en los últimos 12 meses, tanto de carácter homosexual (50%) como heterosexual (45%), con una edad comprendida entre los 18 y los 40 años. El 18,2% eran extranjeros, y el 61,9% se había realizado la prueba anteriormente. Entre los participantes, el porcentaje de pruebas reactivas fue del 2,1%, y la contribución al diagnóstico de nuevos casos de VIH en la Región fue del 4,3%. Conclusiones: Los resultados del estudio ponen de manifiesto que el programa es una herramienta eficaz para el diagnóstico de la infección por VIH en colectivos vulnerables. Además, en el proceso de evaluación se identifican varias oportunidades de mejora como son la accesibilidad al programa y la recogida de información